Canton Strategic Holdings, Inc. (CNTN) Stock Price & Analysis
Canton Strategic Holdings, Inc. (CNTN) closed at USD 1.87 on Thursday, October 15, 2026, up 1.91% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.84; the Oct 15, 2026 session ranged USD 1.76–1.93 on volume of 915,832 shares. Market capitalization is $149.00M, with a 52-week range of USD 1.75–6.89 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CNTN.md
Key facts (CNTN)
- Analysts: None.
- Total return with dividends: 1Y -35.1% vs S&P 500 +18.1%; 5Y -99.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-16, EPS estimate USD —, revenue estimate $0K.
Analysts (CNTN)
Consensus None.
Total return (dividends reinvested) (CNTN)
| 1Y (from 2025-10-16) | 5Y (from 2022-01-10) | |
|---|---|---|
| Total return | -35.1% | -99.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -35.2% | -73.6% |
| Volatility (annualized) | 93.6% | 140.4% |
| Max drawdown | -66.5% (Feb 2026→Oct 2026) | -99.9% (Jan 2022→Apr 2025) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 1.87 |
|---|---|
| Change | ▲ 1.91% (up) |
| Previous Close | USD 1.84 |
| Open | USD 1.76 |
| Day Range | USD 1.76 – 1.93 |
| 52-Week Range | USD 1.75 – 6.89 |
| Volume | 915,832 shares |
| Market Cap | $149.00M |
| Exchange | NCM |
Technical Analysis (CNTN)
Nexqual's technical model rates CNTN "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.46 (neutral) |
| vs SMA50 | Below (USD 2.17) |
| MACD | -0.07 (negative) |
Analyst Ratings (CNTN)
Wall Street analysts rate CNTN "None", per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | None |
|---|
Earnings (CNTN)
| Next Earnings Date | 2026-11-16 |
|---|
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (CNTN)
| Total Revenue | $1.50M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -80.36% |
| Profit Margin | +0.00% |
| ROE | -42.21% |
| Current Ratio | 15.7 |
| Total Cash | $37.24M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (CNTN)
Nexqual rates Canton Strategic Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $37M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$22M (TTM) |
| Efficiency | Critical — ROE -42%, ROA -11.7% |
Ownership (CNTN)
| Insider Ownership | +13.92% |
|---|---|
| Institutional Ownership | +25.22% |
| Shares Outstanding | 79.68M |
| Float | 69.46M |
| Short % of Float | +9.94% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (CNTN)
Canton Strategic Holdings, Inc. is led by Mark Wendland (age 46), CEO & Chairman of the Board, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO & Chairman of the Board | Mark Wendland (age 46) |
|---|---|
| President | Mark Toomey (age 54) |
| Chief Financial Officer | Jacob Asbury (age 51) |
| Chief Operating Officer | Angela Dominy Radkowski (age 36) |
Major Backers & Investors (CNTN)
Notable institutional backers of Canton Strategic Holdings, Inc. include ARK Invest, DRW Securities, LLC, Fidelity, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 9.06% |
| DRW Securities, LLC | 2.16% |
| Fidelity | 1.25% |
| Sumitomo Mitsui Trust Group, Inc. | 0.88% |
| Amova Asset Management Americas Inc | 0.88% |
| Bienville Capital Management, LLC | 0.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.04% |
| BlackRock | 6.62% |
| Geode Capital | 1.78% |
| State Street | 1.17% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt